Why "muscle-sparing" is a marketing term and not a measurement
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Archive — April 2024
Page 2 of 5 of this archive, newest first.
The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Spain after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
New Zealand health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
What the paperwork is for, and who it was designed to protect
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
VendorInvestigate result on a Qingdao retatrutide lot lands 3.6 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
What changed at KP in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
A document, not a test: what a certificate actually is
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Retest date, expiry date, and the two conventions being confused
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
Every fortnight, every third week, seasonally: an unstudied practice
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Shenzhen: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Non-responders, and the honest state of the evidence about them
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Denmark health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
A supplier suspends shipping to France after 21 consecutive customs detentions
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a GL Biochem exenatide lot at 98.1%, against 96.5% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Falling ferritin is not always falling iron
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Qingdao: 17 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
QYB declines, for the 10th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A missed dose, modelled: what happens to retatrutide concentrations over the following fortnight
An accumulation model, drawn from published parameters, with its assumptions stated.
Vitamin D, adiposity, and a volume-of-distribution problem
Micronutrient guidance for this drug class is borrowed almost entirely from post-bariatric surveillance, where the anatomy is different and the deficiency mechanisms are not…
Same material, different gradients, different answers
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Ireland health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What an 11% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What happens when the drug is taken away: three randomised answers
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Freezing a reconstituted vial: the ice-water interface problem
At low concentrations a measurable fraction of peptide can adsorb to glass and plastic surfaces, and the loss is largest exactly where it is least expected.
The number at the bottom of the certificate
A purity percentage is the most quoted figure in the research-peptide trade and one of the least examined. We asked four laboratories to analyse the same vial and got four…
The online reseller trading as Adamant Research Supply closes after 7 years
A proper account of an operation that existed, and of what closing it cost.
Nigeria declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.